Published June 12, 2026 · Auto-generated from the S-1/A filing — every claim sourced.

Kardigan, Inc. (KARD): what the S-1/A says

Kardigan, Inc. has a S-1/A filing dated 2026-06-11 for its NASDAQ listing (US). Expected: Jun 18, 2026 · Price range: $14 – $16 · Offer size: $373,333,344.

Use of proceeds (from the filing)

• We currently intend to use the net proceeds we receive from this offering, together with our existing cash, cash equivalents and short-term investments to fund the clinical development of Danicamtiv, Ataciguat and Tonlamarsen, to fund other research and development activities, and the remainder, if any, for working capital and other general corporate purposes
• Directed share program At our request, the underwriters have reserved up to 5% of the shares of common stock being offered by this prospectus for sale at the initial public offering price to our directors, officers, certain employees, and certain other persons associated with us
• Morgan Securities LLC and its affiliates, an underwriter of this offering, through a directed share program
• We do not know if these persons will choose to purchase all or any portion of these reserved shares, but any purchases they do make will reduce the number of shares of common stock available to the general public
• Except for reserved shares purchased by our executive officers and directors, shares purchased through the directed share program will not be subject to the lock-up agreements with the underwriters described elsewhere in this prospectus
• Any shares sold in the directed share program to our directors or officers who have entered into lock-up agreements with the underwriters will be subject to the provisions of such lock-up agreements

Filing-grounded SWOT (excerpt)

Strengths

Risks / weaknesses

Source: S-1/A on SEC EDGAR · Full research: KARD IPO page (Sharia sector screen, timeline, FAQ).

Research and analysis only — not investment advice, not a recommendation to apply or avoid.